Literature DB >> 2039252

Glucose tolerance in cystic fibrosis.

S Lanng1, B Thorsteinsson, G Erichsen, J Nerup, C Koch.   

Abstract

Glucose tolerance was evaluated in 356 living and dead patients with cystic fibrosis who were recorded at the Danish Cystic Fibrosis Centre. Twenty two patients (6%) were treated elsewhere, 25 (7%) were unable, unwilling or too young (age less than 2 years) to participate; 309 patients (87%) were therefore eligible for the study of whom 99 (32%) were dead and 210 (68%) were alive. Of the dead patients, 13 also had diabetes mellitus (13%). Of the living patients (median age 14 years, range 2-40), nine (4%) were known to have diabetes and all were being treated with insulin. In the remaining 201 patients an oral glucose tolerance test (1.75 g/kg body weight, maximum 75 g) was carried out. A total of 155 patients (74%) had normal glucose tolerance, 31 (15%) had impaired glucose tolerance, and 15 (7%) had diabetes mellitus according to the WHO criteria. The percentage of glycated haemoglobin (HbA1c) (reference range 4.1-6.4%) increased significantly as glucose tolerance decreased: when glucose tolerance was normal the median was 5.2%; when it was impaired the figure was 5.5%; in patients whose diabetes was diagnosed by the oral glucose tolerance test it was 5.9%; and in patients already known to have diabetes mellitus it was 8.6%. The incidence and prevalence of impaired glucose tolerance and diabetes mellitus increased with age. From the age of 15 to 30 years the decrease in the prevalence of normal glucose tolerance was almost linear. Within this age span the proportion of patients with cystic fibrosis with normal glucose tolerance was reduced by roughly 5%/year. Only 35% (95% confidence interval (CI) 22 to 48%) of the patients with cystic fibrosis who were alive at the age of 25 years had normal glucose tolerance; 32% (95% CI 14 to 49%) were diabetic. The prevalence of glucose intolerance in cystic fibrosis is rapidly increasing with age; its potentially harmful effect on the prognosis of cystic fibrosis is of increasing importance as the length of survival of these patients increases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039252      PMCID: PMC1792959          DOI: 10.1136/adc.66.5.612

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  31 in total

1.  Immunotherapy for allergy to insect stings.

Authors:  R F Lockey
Journal:  N Engl J Med       Date:  1990-12-06       Impact factor: 91.245

2.  Endogenous and exogenous insulin responses in patients with cystic fibrosis.

Authors:  E G Wilmshurst; J S Soeldner; D S Holsclaw; R L Kaufmann; H Shwachman; T T Aoki; R E Gleason
Journal:  Pediatrics       Date:  1975-01       Impact factor: 7.124

3.  [Sweat electrolyte analysis by pilocarpine iontophoresis].

Authors:  O H Nielsen; E W Flensborg
Journal:  Ugeskr Laeger       Date:  1981-08-31

4.  Cystic fibrosis in adolescents and adults.

Authors:  P Mitchell-Heggs; M Mearns; J C Batten
Journal:  Q J Med       Date:  1976-07

5.  Carbohydrate tolerance in cystic fibrosis is closely linked to pancreatic exocrine function.

Authors:  M E Geffner; B M Lippe; S A Kaplan; R M Itami; B K Gillard; S R Levin; I L Taylor
Journal:  Pediatr Res       Date:  1984-11       Impact factor: 3.756

6.  Glycosylated haemoglobin and glucose intolerance in cystic fibrosis.

Authors:  P R Stutchfield; S O'Halloran; J D Teale; D Isherwood; C S Smith; D Heaf
Journal:  Arch Dis Child       Date:  1987-08       Impact factor: 3.791

7.  Cystic fibrosis in adolescents and adults.

Authors:  A R Penketh; A Wise; M B Mearns; M E Hodson; J C Batten
Journal:  Thorax       Date:  1987-07       Impact factor: 9.139

8.  Cystic fibrosis: a new outlook. 70 patients above 25 years of age.

Authors:  H Shwachman; M Kowalski; K T Khaw
Journal:  Medicine (Baltimore)       Date:  1977-03       Impact factor: 1.889

9.  [Endocrine pancreas function in mucoviscidosis].

Authors:  G Knöpfle
Journal:  Klin Padiatr       Date:  1985 Jan-Feb       Impact factor: 1.349

10.  Insulin and C-peptide responses to glucose load in cystic fibrosis.

Authors:  V Mohan; V Alagappan; C Snehalatha; A Ramachandran; K V Thiruvengadam; M Viswanathan
Journal:  Diabete Metab       Date:  1985-12
View more
  15 in total

Review 1.  Diabetes mellitus in cystic fibrosis: a review.

Authors:  J A Dodge; G Morrison
Journal:  J R Soc Med       Date:  1992       Impact factor: 5.344

Review 2.  Routine screening for cystic fibrosis-related diabetes.

Authors:  Daniel Peckham
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

3.  Communicating with young adults with cystic fibrosis.

Authors:  A K Webb
Journal:  Postgrad Med J       Date:  1995-07       Impact factor: 2.401

4.  Resting energy expenditure and substrate oxidation rates in cystic fibrosis.

Authors:  I M Bowler; J H Green; S P Wolfe; J M Littlewood
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

5.  Relation between insulin-like growth factor-I, body mass index, and clinical status in cystic fibrosis.

Authors:  A M Taylor; A Bush; A Thomson; P J Oades; J L Marchant; C Bruce-Morgan; J Holly; L Ahmed; D B Dunger
Journal:  Arch Dis Child       Date:  1997-04       Impact factor: 3.791

6.  Glucose tolerance in patients with cystic fibrosis: five year prospective study.

Authors:  S Lanng; A Hansen; B Thorsteinsson; J Nerup; C Koch
Journal:  BMJ       Date:  1995-09-09

7.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

8.  Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis.

Authors:  S Lanng; B Thorsteinsson; J Nerup; C Koch
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

Review 9.  Pancreatic pathophysiology in cystic fibrosis.

Authors:  Katherine N Gibson-Corley; David K Meyerholz; John F Engelhardt
Journal:  J Pathol       Date:  2015-10-01       Impact factor: 7.996

10.  Diminished concentrations of insulin-like growth factor I in cystic fibrosis.

Authors:  E M Laursen; A Juul; S Lanng; N Høiby; C Koch; J Müller; N E Skakkebaek
Journal:  Arch Dis Child       Date:  1995-06       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.